Skip to main content
letter
. 2009 Feb;94(2):298–300. doi: 10.3324/haematol.2008.000059

Figure 2.

Figure 2.

NPM status and cytogenetics at relapse. (A) Leukemic cells retain the aberrant cytoplasmic expression of nucleophosmin (NPM). (B) AML cells show the expected nucleus-restricted positivity for nucleolin/C23. A and B, immuno-alkaline phosphatase anti-alkaline phosphatase (APAAP) technique; × 800; hematoxylin counterstaining. (C) Electropherogram of NPM1 mutation A at relapse. (D) G-banded karyotype at relapse showing 46,XX, der(13;14) (q10;q10), +4.